NASDAQ:MRSN - Mersana Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.30 -0.32 (-4.83 %)
(As of 11/18/2018 07:44 AM ET)
Previous Close$6.30
Today's Range$6.20 - $6.78
52-Week Range$5.56 - $23.96
Volume52,562 shs
Average Volume66,204 shs
Market Capitalization$146.05 million
P/E Ratio-1.96
Dividend YieldN/A
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:MRSN
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio2.86
Quick Ratio3.21


Trailing P/E Ratio-1.96
Forward P/E Ratio-2.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.55 million
Price / Sales8.32
Cash FlowN/A
Price / CashN/A
Book Value$1.29 per share
Price / Book4.88


EPS (Most Recent Fiscal Year)($3.22)
Net Income$-38,700,000.00
Net Margins-440.47%
Return on Equity-110.44%
Return on Assets-49.85%


Outstanding Shares23,180,000
Market Cap$146.05 million
OptionableNot Optionable

Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics Inc (NASDAQ:MRSN) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.16. The business earned $2.15 million during the quarter, compared to the consensus estimate of $3.98 million. Mersana Therapeutics had a negative return on equity of 110.44% and a negative net margin of 440.47%. View Mersana Therapeutics' Earnings History.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Mersana Therapeutics.

What price target have analysts set for MRSN?

6 equities research analysts have issued 1-year price objectives for Mersana Therapeutics' shares. Their forecasts range from $16.00 to $61.00. On average, they expect Mersana Therapeutics' share price to reach $28.60 in the next twelve months. This suggests a possible upside of 354.0% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.

What is the consensus analysts' recommendation for Mersana Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.

Has Mersana Therapeutics been receiving favorable news coverage?

News stories about MRSN stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mersana Therapeutics earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the next few days.

Who are some of Mersana Therapeutics' key competitors?

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the folowing people:
  • Ms. Anna Protopapas, Pres, CEO & Director (Age 54)
  • Mr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 54)
  • Dr. Donald A. Bergstrom, Former Sr. VP & Chief Medical Officer (Age 46)
  • Mr. Mikhail Papisov Ph.D., Co-Founder
  • Mr. Wayne Foster, VP of Fin.

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.43%), EcoR1 Capital LLC (2.14%), JPMorgan Chase & Co. (1.38%), JPMorgan Chase & Co. (1.38%), Allianz Asset Management GmbH (0.20%) and American Century Companies Inc. (0.05%). Company insiders that own Mersana Therapeutics stock include M James Barrett and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.

Which major investors are selling Mersana Therapeutics stock?

MRSN stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc. and Allianz Asset Management GmbH. View Insider Buying and Selling for Mersana Therapeutics.

Which major investors are buying Mersana Therapeutics stock?

MRSN stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, JPMorgan Chase & Co., JPMorgan Chase & Co. and BlackRock Inc.. View Insider Buying and Selling for Mersana Therapeutics.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $6.30.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $146.05 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]

MarketBeat Community Rating for Mersana Therapeutics (NASDAQ MRSN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by Staff

Featured Article: What is Liquidity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel